Business Wire

Reality TV Star, Mollie Pearce, Backs Campaign to Tackle Inequalities in Condition That Impacts Millions of People Globally


Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where’s Crohn’s & Colitis (CC)? campaign for this year’s World IBD Day (19 May 2024).

The campaign focuses on access to IBD care and treatment as the burden of the condition rises globally1. Widening inequalities and significant variations in access across the globe, and even within countries, is impacting people’s experience of IBD care and ultimately their outcomes2.

Through raising awareness of the factors driving these inequalities and potential solutions, the campaign hopes to encourage improved access to a timely diagnosis, high quality care and innovative treatments.

Innovations in treatments, including advances in treatment administration that enable people to access at-home injectable treatment (versus hospital-based treatment), allows people to have an improved quality of life whilst managing their condition3.

The campaign encourages people to look beyond what they would usually see, to make the invisible condition, visible. In doing so, users are taken on a journey across borders to explore inequalities in IBD at a global scale and how these could be overcome.

Reality TV star Mollie Pearce, a contestant on the popular UK show ‘The Traitors’, partners with Celltrion to launch the campaign. Mollie was diagnosed with UC when she was 11 years old and has openly shared her experiences living with the disease as an advocate for the IBD community, breaking down stigma and inspiring others to seek the care that works best for them.

Mollie Pearce, media personality and finalist on ‘The Traitors’, commented: “Living with a condition such as UC comes with so many challenges - from sometimes not being able to leave the house to missing out on social occasions with friends. That’s why I’m so passionate about being an advocate for the IBD community and helping others to break down barriers and do the things they never thought were possible once they were diagnosed.

“The Where’s CC? campaign is really close to my heart. I want to do all I can to ensure everyone is treated as an individual and gets the care they deserve.”

Mr. Kevin Byoung Seo Choi, Executive VP and head of the marketing division at Celltrion, said: “It is simply unacceptable that there are so many barriers in accessing IBD care. From geographic disparities in access to infusion centers to health system limitations and education, there is an urgent need to tackle the root cause of inequalities globally so that all patients can access potentially life-changing therapies.

“We are committed to tackling inequalities and ensuring a sustainable future for all IBD patients. The Where’s CC? campaign is our latest step in making this a reality through raising awareness and advocating for change.”

The first instalment of the Where’s CC? campaign, launched for World IBD Day 2023, focused on age-related inequalities in IBD, and how the challenges that come with the condition can vary at different stages of life.

Visit to learn more about the Where’s CC? campaign and inequalities in access to care and treatment in IBD, and how these can be overcome to improve IBD outcomes for all.

World IBD Day is an annual awareness campaign led by patient organisations representing over 50 countries on five continents and coordinated by the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA)4.

IBD is an umbrella term used to describe conditions including Crohn’s disease and ulcerative colitis. Collectively, IBD impacts over 10 million people worldwide with incidence rates rapidly increasing across the world5.

IBD is a long-term condition and there may be times when the symptoms are severe, known as a flare-up, and times when there are no or few symptoms, known as remission. Common symptoms of IBD include pain, cramping or swelling in the stomach, episodes of diarrhoea, weight loss and extreme tiredness6. IBD can appear for the first time at any age, however, diagnosis most commonly takes place between the ages of 10 and 405.

Treatment for IBD can be transformative for patients’ lives, reducing the impact of the condition on their lives by minimising flare-ups and maintaining remission. In recent years, the increasing availability of new treatments has transformed IBD patient care.

‘The Traitors’ is a British reality TV series involving a group of players who are seemingly focused on a common goal – the ‘faithfuls’ must eliminate all the ‘traitors’ from the group. Mollie Pearce appeared in Series Two of the programme, making it to the final where she cast the deciding vote of the series.

Celltrion is a leading biopharmaceutical company that specializes in research, development and manufacturing of innovative therapeutics that improve people's lives worldwide. The company’s portfolio of anti-TNF therapies spans a number of indications across distinct therapy areas: immunology, hemato-oncology and ophthalmology. We are dedicated to expanding patient access to life-changing biologic therapies while generating healthcare sustainability with meaningful cost savings for patients worldwide. To learn more, please visit

Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion/Celltrion Healthcare that may constitute forward-looking statements, under pertinent securities laws.

These statements may be identified by words such as “prepares”, “hopes to”, “upcoming”, ”plans to”, “aims to”, “to be launched”, “is preparing, “once gained”, “could”, “with the aim of”, “may”, “once identified”, “will”, “working towards”, “is due”, “become available”, “has potential to”, the negative of these words or such other variations thereon or comparable terminology.

In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion/Celltrion Healthcare's management, of which many are beyond its control.

Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.

Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this presentation are based upon what management of Celltrion/Celltrion Healthcare believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Celltrion/Celltrion Healthcare undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.


1 The Lancet Gastroenterology & Hepatology. Promoting equity in inflammatory bowel disease: a global approach to care. Available at: [Accessed: May 2024]

2 Journal of Crohn’s and Colitis. P018 Inequalities in healthcare access, experience and outcomes in adults with Inflammatory Bowel Disease: A scoping review. Available at: [Accessed: May 2024]

3 BMC Proceedings. Intravenous versus subcutaneous delivery of biotherapeutics in IBD: an expert’s and patient’s perspective. Available at:,are%20able%20to%20administer%20their%20treatments%20at%20home. [Accessed: May 2024]

4 EFCCA. World IBD Day. Available at: [Accessed: May 2024]

5 EFCCA. What is IBD? Available at: [Accessed: May 2024]

6 NHS. Inflammatory bowel disease. Available at: [Accessed: May 2024]

To view this piece of content from, please give your consent at the top of this page.

Contact information

Holly Barber
+44 (0) 7759 301620

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

EASA Certifies LEAP-powered Airbus A321XLR19.7.2024 15:14:00 CEST | Press release

CFM International is celebrating certification of the LEAP-powered Airbus A321XLR by the European Union Aviation Safety Agency (EASA). The A321XLR marks the fifth member of the A320neo family aircraft powered by LEAP engines. Supporting aircraft certification were updates to the engine’s type certificates, which EASA and the U.S. Federal Aviation Administration (FAA) granted on July 10. “Certification of the CFM-powered A321XLR is an important milestone in providing our operators much greater route scheduling flexibility,” said Gaël Méheust, president and CEO of CFM International. “The engine was always designed with 35,000-lb. thrust capability for longer range, higher max takeoff weight aircraft. As a result, no engine modifications were required, giving operators the added benefit of 100 percent commonality with their existing A320neo family fleets.” As the aviation industry gathers at the Farnborough International Airshow, trade visitors will be able to see the LEAP-powered A321XLR

Textron Aviation Bolsters Support in the United Kingdom and Ireland Through Expanded Relationship With Gama Aviation (UK) Limited19.7.2024 15:00:00 CEST | Press release

Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced at the Royal International Air Tattoo (RIAT) that the company is expanding its relationship with longtime channel partner Gama Aviation. Newly designated as an Authorized Sales Representative (ASR) for Textron Aviation Special Missions aircraft in the United Kingdom and Ireland, Gama Aviation will now feature special missions variants of the entire portfolio of Cessna and Beechcraft aircraft. This press release features multimedia. View the full release here: Textron Aviation | Textron Aviation expanding relationship with channel partner Gama Aviation (Photo: Business Wire) “With an established and growing base of our special missions aircraft in the United Kingdom and Ireland, Textron Aviation is continuously investing in providing the best aviation experience for customers,” said Bob Gibbs, vice president, Special Mission Sales, Textron Aviation. “Gama

Qualcomm Schedules Third Quarter Fiscal 2024 Earnings Release and Conference Call19.7.2024 15:00:00 CEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced that it will publish the Company’s financial results for its third quarter fiscal 2024 on Wednesday, July 31, 2024, after the close of the market on the Company’s Investor Relations website, at The earnings release will also be furnished to the Securities and Exchange Commission (SEC) on a Form 8-K, which will be available on the SEC website at Qualcomm will host a conference call to discuss its third quarter fiscal 2024 results which will be broadcast live on July 31, 2024, beginning at 1:45 p.m. Pacific Time (PT) at An audio replay will be available at and via telephone following the live call for 30 days thereafter. To listen to the replay via telephone, U.S. callers may dial (877) 660-6853 and international callers may dial (201) 612-7415. Callers should use re

GE Aerospace Investing $1 Billion to Expand and Upgrade MRO Facilities Worldwide19.7.2024 13:55:00 CEST | Press release

GE Aerospace (NYSE:GE) announced plans to invest more than $1 billion over five years in its Maintenance, Repair and Overhaul (MRO) and component repair facilities worldwide. These investments will help GE Aerospace create capacity to meet growth in both the widebody and narrowbody installed base by adding additional engine test cells and equipment. The funding also will add cutting-edge technology, including enhanced inspection techniques, to reduce turnaround times for customers as well as expand component repair capability within its overhaul shops. GE Aerospace President and CEO, Commercial Engines and Services, Russell Stokes said, “Our customers are experiencing strong air travel demand, and we are investing to increase our capacity and efficiency so we can meet their growing needs and keep their planes flying safely and reliably. With this major investment, we are reinforcing our longstanding focus on safety, quality, and delivery for our customers and the flying public.” The la

SLB Announces Second-Quarter 2024 Results19.7.2024 12:50:00 CEST | Press release

Regulatory News: This press release features multimedia. View the full release here: The exterior of the SLB headquarters in Houston, Texas. (Photo: Business Wire) SLB (NYSE: SLB) today announced results for the second-quarter 2024. Second-Quarter Results (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2024 Mar. 31, 2024 Jun. 30, 2023 Sequential Year-on-year Revenue $9,139 $8,707 $8,099 5% 13% Income before taxes - GAAP basis $1,421 $1,357 $1,293 5% 10% Income before taxes margin - GAAP basis 15.5% 15.6% 16.0% -4 bps -42 bps Net income attributable to SLB - GAAP basis $1,112 $1,068 $1,033 4% 8% Diluted EPS - GAAP basis $0.77 $0.74 $0.72 4% 7% Adjusted EBITDA* $2,288 $2,057 $1,962 11% 17% Adjusted EBITDA margin* 25.0% 23.6% 24.2% 142 bps 81 bps Pretax segment operating income* $1,854 $1,649 $1,581 12% 17% Pretax segment operating margin* 20.3% 18.9% 19.5% 135 bps 76 bps Net income attributable to

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye